Omega Pacific Resources Inc
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2016-01-01
- Employees
- 94
- Market Cap
- $81M
- Introduction
Omega Pacific Resources Inc is engaged in the business of mineral exploration in Canada. It mainly engages in the acquisition, exploration, and development of mineral exploration properties. It holds an interest in the Lekcin property located in the New Westminster Mining Division, British Columbia, Canada.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene
- Conditions
- Hepatocellular CarcinomaSolid TumorHepatocellular Carcinoma Non-resectableHepatocellular Carcinoma RecurrentHepatocellular CancerLiver CancerLiver, Cancer Of, Non-Resectable
- Interventions
- Drug: Checkpoint Inhibitor, Immune
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Omega Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT05497453
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Florida Health Cancer Center, Gainesville, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
News
Flagship-Backed Omega Therapeutics Files for Bankruptcy, Halts Cancer Drug Development
• Omega Therapeutics announces plans to file Chapter 11 bankruptcy following the suspension of its lead cancer drug program OTX-2002, with Flagship's Pioneering Medicines offering a $1.4 million bridge loan. • The genetic medicines company received a Nasdaq delisting notice in January 2024, marking a significant downturn since its $126 million IPO in 2021. • As part of restructuring, Omega will lay off 17 employees while negotiating asset sales, including its obesity program partnership with Novo Nordisk.
GSK and Flagship Pioneering Launch $7 Billion Strategic Alliance for Novel Therapeutics Development
• GSK and Flagship Pioneering have established a strategic partnership worth potentially $7 billion to develop 10 new medicines and vaccines, with an initial focus on respiratory and immunological diseases. • The collaboration begins with a joint investment of $150 million, with each program eligible for up to $720 million in milestone payments plus royalties from GSK. • This partnership follows Flagship's successful collaborations with other major pharmaceutical companies, including Pfizer and Novo Nordisk, reinforcing their platform-based biotech development model.